Pharsight

Xeglyze patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9839631 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9357783 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(9 months from now)

US8212038 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(9 months from now)

US7812163 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Oct, 2026

(3 years from now)

US10292389 DR REDDYS LABS SA Pediculicidal composition
Dec, 2034

(11 years from now)

Xeglyze is owned by Dr Reddys Labs Sa.

Xeglyze contains Abametapir.

Xeglyze has a total of 5 drug patents out of which 0 drug patents have expired.

Xeglyze was authorised for market use on 24 July, 2020.

Xeglyze is available in lotion;topical dosage forms.

Xeglyze can be used as topical treatment of head lice infestation in patients 6 months of age and older.

Drug patent challenges can be filed against Xeglyze from 2024-07-24.

The generics of Xeglyze are possible to be released after 17 December, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: 2024-07-24

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

XEGLYZE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic